Public market insider buying at Aurora Cannabis (T:ACB)

Miguel Martin, CEO, acquired 60,956 Common Shares on a direct ownership basis at a price of $1.607USD on June 8th, 2022. This represents a $122,814 investment into the company's shares and an account share holdings change of 89.7%.

William Glen Ibbott, CFO, acquired 38,262 Common Shares on a direct ownership basis at prices ranging from $1.940 to $1.960 on June 7th, 2022. This represents a $74,988 investment into the company's shares and an account share holdings change of greater than 100%.

Aurora Cannabis is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The Company's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. It produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others. Aurora Cannabis Inc. (ACB) has below median officer and director direct ownership compared to its small-cap peers in the market, based on our estimate using SEDI data. According to regulatory filings yesterday, two insiders have invested a total amount of $197,803.